GSK Strengthens Gastrointestinal Cancer Portfolio with IDRx Buyout
GSK, a British pharmaceutical company, said Monday that it will pay up to $1.15 billion to purchase IDRx, a biopharmaceutical company based in Boston,
GSK, a British pharmaceutical company, said Monday that it will pay up to $1.15 billion to purchase IDRx, a biopharmaceutical company based in Boston, to create a cure for gastrointestinal stromal tumours. The agreement, which aims to strengthen GSKs growing portfolio in gastrointestinal malignancies, involves a $1 billion upfront payment. According to Luke Miels, GSKs chief commercial officer, the companys strategy of focussing on verified assets that address critical medical needs is in line with this acquisition, given the difficulties the company is facing in its vaccine market. The acquisition demonstrates GSKs dedication to improving cancer care in the face of changing consumer needs.
Read More..
B2B Tech News | 10 days ago